Fig. 6. NSC-622608 synergizes with TKIs to promote apoptosis in CML cells. (A) CCK-8 results showing the effect of combination treatment with TKIs (das: 0, 0.5, 1, 5, 10, and 25 nM; OL: 0, 1, 5, 10, 50, and 100 nM) and NSC-622608 (50 μM) on KBM5 and KBM5-T315I cells (p<0.01, p<0.05). (B, C) Drug synergy experiment on TKIs and NSC-622608, and the data were analyzed by CompuSyn: additive effect (CI=1), synergistic effect (CI<1), and antagonistic effect (CI>1). Das and NSC622608 (CI=0.339), Das and NSC622608 (CI=0.293), (D-F) Flow cytometry results showing the greatest proportion of apoptotic cells in the combination, TKI and NSC622608 groups compared with the single drug group (p<0.01, p<0.05; bar: 50 μm). Asterisks (*) indicate significance, ** indicates p<0.01, * indicates p<0.05, and NS indicates no significance.
© Biomolecules & Therapeutics
